Olmesartan Milpharm (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartan Milpharm, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and is prescribed for adults who need blood pressure control.

GNH USA supplies Olmesartan Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Milpharm is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower elevated blood pressure. - Hypertension: Helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: Provides renal protection by lowering intraglomerular pressure. - Heart failure prevention: Assists in preventing progression of heart failure in high‑risk patients.

Adverse reactions to olmesartan may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory infection

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevation - Bullous pemphigoid (rare skin disorder)

When prescribing Olmesartan Milpharm, clinicians should consider several safety aspects. - Renal function monitoring: Assess baseline kidney function and adjust as needed. - Electrolyte balance: Monitor serum potassium, especially if combined with potassium‑sparing agents. - Hypotension risk: Caution in patients prone to low blood pressure or on diuretics. - Pregnancy: Avoid use during pregnancy due to potential fetal harm. - Drug interactions: Review concomitant medications for additive blood‑pressure effects. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan Milpharm can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Aliskiren (combined use in diabetes is contraindicated). - Potassium‑rich supplements or potassium‑sparing diuretics (risk of hyperkalemia). - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) (may blunt antihypertensive effect). - Lithium (increased lithium levels). - Cyclosporine or tacrolimus (possible rise in serum creatinine).